Tempest Therapeutics Inc Stock Price, News & Analysis

Tempest Therapeutics (Nasdaq: TPST) announced the acceptance of a presentation for TPST-1495 at the Society for Immunotherapy of Cancer’s 36th Annual Meeting scheduled for November 10-14, 2021. The presentation, titled "Dual blockade of the EP2 and EP4 PGE2 receptors with TPST-1495 is an optimal approach for drugging the prostaglandin pathway", will highlight preclinical studies showing TPST-1495's enhanced efficacy over single antagonists against tumor progression and immune suppression. Tempest is currently advancing TPST-1495 in a Phase 1a/1b clinical trial targeting advanced solid tumors.

Tempest Therapeutics (TPST) has announced the start of a Phase 1b/2 clinical study for TPST-1120, a PPAR⍺ antagonist, in combination with atezolizumab and bevacizumab for advanced hepatocellular carcinoma (HCC). The trial, conducted in partnership with Roche, will assess the safety and anti-tumor activity of this combination in up to 60 patients across multiple sites. HCC presents significant treatment challenges, highlighting the need for new therapy options. Tempest retains global rights to TPST-1120, which has shown promise in preclinical studies.

Tempest Therapeutics (Nasdaq: TPST) announced on September 13, 2021, the appointment of Russell Vance, PhD, to its advisory board and an exclusive licensing agreement with the University of California at Berkeley. This license covers a new drug target identified in Dr. Vance's lab, which has potential implications for cancer treatment. Dr. Vance's research focuses on a pathway involved in immune response and tumor metastasis. The company continues to advance its clinical programs, including TPST-1495 and TPST-1120, both currently in Phase 1 studies.

Tempest Therapeutics, Inc. (Nasdaq: TPST) has announced its participation in two upcoming investor conferences in September 2021. The company will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 a.m. ET and at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22 at 9:55 a.m. ET. Tempest is progressing its clinical-stage oncology programs, including TPST-1495 and TPST-1120, which target cancer treatment through innovative mechanisms. For more details, visit the Tempest investor website.

Science 37 has appointed Christine Pellizzari as the new Chief Legal Officer, bringing nearly 30 years of legal experience to enhance the company's mission of accelerating clinical trials. Previously serving at Insmed, Pellizzari's expertise will support Science 37's global expansion and improve access to clinical research for patients and providers. CEO David Coman emphasized her qualifications as instrumental in navigating the evolving decentralized clinical trial landscape.

Tempest Therapeutics (TPST) successfully completed a merger, raising $30M through a PIPE, boosting its cash reserves to $68.5M. The company advanced its clinical programs, including TPST-1495 and TPST-1120, showing promising results in patient trials. The net loss for Q2 2021 was $7.1M, higher than the previous year's $5.2M, mainly due to merger-related expenses. R&D expenses increased slightly to $4.2M. Looking forward, significant milestones are expected in 2022, including new studies for TPST-1495 and TPST-1120.

Tempest Therapeutics (Nasdaq: TPST) announced the appointment of Dr. Ronit Simantov to its board of directors, enhancing its leadership in oncology. Dr. Simantov brings over 20 years of experience from roles at Gamida Cell and Pfizer, where she led significant oncology programs. CEO Steve Brady expressed enthusiasm for her insights as Tempest advances its clinical programs, especially with its candidate therapies TPST-1495 and TPST-1120. This appointment aims to strengthen the company’s position in the competitive oncology landscape and expand its strategic oversight.

Tempest Therapeutics (Nasdaq: TPST) announced that Dr. Sam Whiting, the chief medical officer, will join a panel titled “Developing Therapies for the Next Immuno-Oncology Targets” at the William Blair 2021 Biotech Focus Conference on July 14, 2021, at 2:10 p.m. ET. Tempest is advancing clinical programs TPST-1495 and TPST-1120, which target EP2/EP4 and PPARα, respectively, through Phase 1 studies. The company aims to develop innovative therapies combining targeted and immune-mediated mechanisms to treat various tumors. More details are available on their investor website.

Tempest Therapeutics (Nasdaq: TPST) has appointed Christine Pellizzari, a 20-year industry veteran, to its Board of Directors. CEO Steve Brady emphasized the importance of her broad experience in supporting the company’s growth and advancing its oncology pipeline. Pellizzari, currently the chief legal officer at Insmed, has a strong background in legal and regulatory affairs, having overseen successful IPOs and compliance infrastructure in previous roles. Tempest continues to develop its promising clinical programs, TPST-1495 and TPST-1120, which are in Phase 1 studies for cancer treatment.